Search research articles
Contact Us
Filters
Showing results (51-60 of 365) with videos related to
Page
of 37
Sort By:
The Oncologist
|
February 25, 2020
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature
Miruna Grecea, Aurélien Marabelle, Samy Ammari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 2021
Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks
Arnaud Bayle, Antoine Hollebecque, Barbara Pistilli, et al.
Bulletin Du Cancer
|
January 1, 2019
Benoîte Mery, Antoine Thiery-Vuillemin, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2026
The evolving landscape of early-phase oncology: Toward more precise drug development
Camille Mazza, Matthieu Roulleaux Dugage, Antoine Italiano, et al.
The Oncologist
|
November 4, 2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting
Oliver Sartor, Ross M Michels, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 4, 2022
Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox
Arnaud Bayle, Antoine Italiano, Christophe Massard, et al.
American Journal of Clinical Oncology
|
March 22, 2012
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?
Charles Ferté, Christophe Massard, Ariel Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale
Karim Amrane, Coline LE Meur, Christos Chouaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2026
Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization
Paul Matte, Matthieu Delaye, Yohann Loriot, et al.
Expert Opinion on Drug Safety
|
May 5, 2016
Safety of available treatment options for renal cell carcinoma
Lisa Derosa, Laurence Albiges, Christophe Massard, et al.
Page
of 37
Search research articles
Search
Showing results (51-60 of 365) with videos related to
Sort By:
Page
of 37
The Oncologist
|
February 25, 2020
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature
Miruna Grecea, Aurélien Marabelle, Samy Ammari, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 2021
Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks
Arnaud Bayle, Antoine Hollebecque, Barbara Pistilli, et al.
Bulletin Du Cancer
|
January 1, 2019
Benoîte Mery, Antoine Thiery-Vuillemin, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2026
The evolving landscape of early-phase oncology: Toward more precise drug development
Camille Mazza, Matthieu Roulleaux Dugage, Antoine Italiano, et al.
The Oncologist
|
November 4, 2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting
Oliver Sartor, Ross M Michels, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 4, 2022
Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox
Arnaud Bayle, Antoine Italiano, Christophe Massard, et al.
American Journal of Clinical Oncology
|
March 22, 2012
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?
Charles Ferté, Christophe Massard, Ariel Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2026
Overcoming anti-PD-L1 resistance with anti-PD1 therapy: A case report and putative rationale
Karim Amrane, Coline LE Meur, Christos Chouaid, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2026
Evaluation of renal exclusion criteria in early phase oncology trials: A call for modernization
Paul Matte, Matthieu Delaye, Yohann Loriot, et al.
Expert Opinion on Drug Safety
|
May 5, 2016
Safety of available treatment options for renal cell carcinoma
Lisa Derosa, Laurence Albiges, Christophe Massard, et al.
Page
of 37